|
|
700 Pennsylvania Drive
Exton, PA 19341 USA
phone:484-595-1500
fax:
|
|
| Symbol |
ADLR |
| Exchange |
NASDAQ |
| Founded |
1994 |
| Employees |
122 |
|
|
| www.adolor.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Prescription pain management products. |
|
| Management |
| Michael R. Dougherty, President and Chief Executive Officer; Stephen W. Webster, Senior Vice President, Finance and Chief Financial Officer; John M. Limongelli, Esq., Senior Vice President, General Counsel and Secretary |
| |
|
|
|
|
|
|
|
| Keywords |
| opioids, morphine, gastrointestinal, postoperative, ileus |
|
|
|
| Description |
|
Adolor Corporation is developing analgesics and other related therapeutics based upon recent advances in proprietary medicinal chemistry and recombinant receptor technology. It specializes in the discovery, development and commercialization of prescription pain management products. |
|
| Products / Services |
Entereg (alvimopan), Adolor's lead product candidate, is being developed to manage postoperative ileus, the gastrointestinal side effect which can affect millions of patients following many types of surgery. Entereg is also being developed to manage the bowel dysfunction which can negatively impact the quality of life for millions of patients using opioid analgesic products such as morphine for treating pain, as well as being developed for treating chronic constipation in patients not using opioids. Adolor is collaborating with GlaxoSmithKline for the development and commercialization of Entereg. Adolor's next product candidate is a sterile lidocaine patch in clinical development for treating postoperative incisional pain. Adolor also has a number of discovery research programs focused on the identification of novel compounds for the treatment of pain.
|
|
| Market / Customers |
Over 100 million patients experience acute or chronic pain annually in the United States, and there is a large window of opportunity for more effective analgesics with fewer side effects. Adolor's product candidates are designed to address commercial opportunities in several market segments of more than $1 billion each. Alvimopan is for the management of post-operative ileus, which is a temporary impairment of gastrointestinal motility after abdominal or other surgeries.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
